FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:286-291 February 1, 1996 Number 5 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Graft-versus-host disease (GVHD) caused by poorly defined minor (i.e., other than HLA) histocompatibility antigens remains a serious problem in recipients of bone marrow transplants. We sought to determine whether the CD31 adhesion molecule is a minor alloantigen.

Methods We directly sequenced samples of complementary DNA (cDNA) encoding CD31 molecules from 21 unrelated normal subjects. Sequence-specific primers were then designed to amplify alleles by the polymerase chain reaction, thereby permitting CD31 typing of genomic DNA from additional normal subjects. To assess the relevance of CD31 matching to bone marrow transplantation, we performed CD31 typing of 46 recipients of bone marrow (32 without GVHD and 14 with severe [grade III or IV] acute GVHD) and their HLA-identical sibling donors. The immunoreactivity of CD31 phenotypes with anti-CD31 monoclonal antibodies was compared by flow cytometry.

Results Direct sequencing of cDNA for CD31 from the 21 normal subjects identified a single polymorphism, CTGGTG (LeuVal), at codon 125; we designated the resulting alleles CD31.L and CD31.V, respectively. The CD31 genotypes of these and 142 other unrelated subjects were of the expected frequencies. Among the transplant recipients, 71 percent of those with acute GVHD had CD31 genotypes that were not identical to the donor's genotype, as compared with 22 percent of the recipients without GVHD (P = 0.004). The binding of anti-CD31 monoclonal antibodies as measured by fluorescence-activated cell sorting correlated with the CD31 types of homozygous cell lines.

Conclusions The adhesion molecule CD31 is polymorphic. When donor and recipient genotypes are not identical, the risk of GVHD increases. Prospective CD31 typing may reduce the risk of acute GVHD.

Source Information

From the Departments of Pathology (E.B., D.D.H., S.K., J.L.Z., F.C.G.), Medicine (N.J.C., J.L.Z.), and Health Research and Policy (B.W.B.), Stanford University, Stanford, Calif.

Address reprint requests to Dr. Grumet at the Stanford University Blood Center, 800 Welch Rd., Palo Alto, CA 94304.

Full Text of this Article

This article has been cited by other articles:

• Wu, Y., Tworkoski, K., Michaud, M., Madri, J. A. (2009). Bone Marrow Monocyte PECAM-1 Deficiency Elicits Increased Osteoclastogenesis Resulting in Trabecular Bone Loss. J. Immunol. 182: 2672-2679 [Abstract] [Full Text]  
• Gallay, N., Anani, L., Lopez, A., Colombat, P., Binet, C., Domenech, J., Weksler, B. B., Malavasi, F., Herault, O. (2007). The Role of Platelet/Endothelial Cell Adhesion Molecule 1 (CD31) and CD38 Antigens in Marrow Microenvironmental Retention of Acute Myelogenous Leukemia Cells. Cancer Res. 67: 8624-8632 [Abstract] [Full Text]  
• Deaglio, S., Vaisitti, T., Aydin, S., Ferrero, E., Malavasi, F. (2006). In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 108: 1135-1144 [Abstract] [Full Text]  
• Harashima, N., Kurihara, K., Utsunomiya, A., Tanosaki, R., Hanabuchi, S., Masuda, M., Ohashi, T., Fukui, F., Hasegawa, A., Masuda, T., Takaue, Y., Okamura, J., Kannagi, M. (2004). Graft-versus-Tax Response in Adult T-Cell Leukemia Patients after Hematopoietic Stem Cell Transplantation. Cancer Res. 64: 391-399 [Abstract] [Full Text]  
• Deaglio, S., Capobianco, A., Bergui, L., Durig, J., Morabito, F., Duhrsen, U., Malavasi, F. (2003). CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 102: 2146-2155 [Abstract] [Full Text]  
• Heslop, H. E., Stevenson, F. K., Molldrem, J. J. (2003). Immunotherapy of Hematologic Malignancy. ASH Education Book 2003: 331-349 [Abstract] [Full Text]  
• Barrett, A. J., Rezvani, K., Solomon, S., Dickinson, A. M., Wang, X. N., Stark, G., Cullup, H., Jarvis, M., Middleton, P. G., Chao, N. (2003). New Developments in Allotransplant Immunology. ASH Education Book 2003: 350-371 [Abstract] [Full Text]  
• Rocha, V., Franco, R. F., Porcher, R., Bittencourt, H., Silva, W. A. Jr, Latouche, A., Devergie, A., Esperou, H., Ribaud, P., Socie, G., Zago, M. A., Gluckman, E. (2002). Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 100: 3908-3918 [Abstract] [Full Text]  
• Andreotti, F, Porto, I, Crea, F, Maseri, A (2002). Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 87: 107-112 [Abstract] [Full Text]  
• Kroll, H., Sun, Q.-H., Santoso, S. (2000). Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia. Blood 96: 1409-1414 [Abstract] [Full Text]  
• Nakada, M. T., Amin, K., Christofidou-Solomidou, M., O'Brien, C. D., Sun, J., Gurubhagavatula, I., Heavner, G. A., Taylor, A. H., Paddock, C., Sun, Q.-H., Zehnder, J. L., Newman, P. J., Albelda, S. M., DeLisser, H. M. (2000). Antibodies Against the First Ig-Like Domain of Human Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) That Inhibit PECAM-1-Dependent Homophilic Adhesion Block In Vivo Neutrophil Recruitment. J. Immunol. 164: 452-462 [Abstract] [Full Text]  
• Maruya, E., Saji, H., Seki, S., Fujii, Y., Kato, K., Kai, S., Hiraoka, A., Kawa, K., Hoshi, Y., Ito, K., Yokoyama, S., Juji, T. (1998). Evidence That CD31, CD49b, and CD62L Are Immunodominant Minor Histocompatibility Antigens in HLA Identical Sibling Bone Marrow Transplants. Blood 92: 2169-2176 [Abstract] [Full Text]  
• Aractingi, S., Chosidow, O. (1998). Cutaneous Graft-versus-Host Disease. Arch Dermatol 134: 602-612 [Abstract] [Full Text]  
• Da Costa, L., Charron, D., Loiseau, P. (1997). Does the Adhesion Molecule CD31 Act as a Minor Histocompatibility Antigen?. Blood 90: 1332-1332 [Full Text]  
• Kernan, N. A., Dupont, B. (1996). Minor Histocompatibility Antigens and Marrow Transplantation. NEJM 334: 323-324 [Full Text]